OVID Insider Trading

Ovid Therapeutics Inc. (OVID) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $408.7M, listed on NASDAQ, employing roughly 23 people, carrying a beta of 0.23 to the broader market. Ovid Therapeutics Inc. Led by Margaret Alexander, public since 2017-05-05.

In the last 12 months, Ovid Therapeutics Inc. insiders made 3 buy transactions and 2 sale transactions.

DateNameTypeSharesPriceValue
Jul 8, 2026Carter Charles RossA-Award50,000$0.00$0
Jul 8, 2026Carter Charles Ross0$0.00$0
Jul 8, 2026Carter Charles Ross200,000$1.14$228.0K
Jul 8, 2026Carter Charles Ross206,250$1.65$340.3K
Jun 17, 2026Greka AnnaA-Award130,000$2.26$293.8K
Jun 17, 2026Greka Anna0$0.00$0
Apr 9, 2026PAPADOPOULOS STELIOSA-Award17,578$2.56$45.0K
Apr 9, 2026Friedman BartA-Award8,789$2.56$22.5K
Apr 9, 2026Fitzgerald Kevin JosephA-Award17,578$2.56$45.0K
Mar 25, 2026LEVIN JEREMY MM-Exempt47,333$1.40$66.3K

OVID Insider Activity by Quarter

Reported Form 4 and Form 5 lines under OVID's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to May 10, 2017, and a quarter counts only when every filing for it was read. 1 line filed under another SEC company ID is not counted.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A0N/A0
Q3 20260N/A0N/A1
Q2 20260N/A0N/A4
Q1 20260N/A2$29.3K12
Q4 20250N/A0N/A7
Q3 20250N/A0N/A0
Q2 20250N/A0N/A0
Q1 20251$5.0K2$5.1K10
Q4 20240N/A0N/A4

Filings Under Another SEC Company ID

1 filing line on file was filed under an SEC company ID (CIK) other than OVID's (1636651). Such a filing can be a predecessor company's (one that reorganized, redomiciled or converted files under a new CIK), a former holder of the OVID ticker's, or another company's that OVID or its insiders report holding; the CIK alone does not say which. It is not counted in the figures above.

CIKLinesDatesSecurities
13950641Jul 1, 2022Series A Convertible Preferred Stock

OVID Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 131 institutions reported holding 147,020,696 OVID shares, valued at $395.6M as reported, 210.4% of its market cap (market cap of Jun 26, 2026). That is +28 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 46 opened a position, 17 closed one, 33 added and 27 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
Jupiter Topco LLC20,741,234$55.9MNo comparable report
EVENTIDE ASSET MANAGEMENT, LLC11,812,241$31.8M+1,895,330
BlackRock, Inc.10,823,480$29.1M+9,290,197
RA CAPITAL MANAGEMENT, L.P.10,500,968$28.2M-213,032
Affinity Asset Advisors, LLC10,144,562$27.3M-491,756
STATE STREET CORP7,900,765$21.3M+7,380,482
VANGUARD CAPITAL MANAGEMENT LLC7,760,114$20.9M+2,501,868
ADAR1 Capital Management, LLC7,417,479$20.0M+2,873,366
Balyasny Asset Management L.P.6,719,076$18.1M+1,186,003
ADAGE CAPITAL PARTNERS GP, L.L.C.6,163,781$16.6MUnchanged

By Quarter

QuarterInstitutionsSharesValue
Q2 2026131147,020,696$395.6M
Q1 2026103105,066,118$233.2M
Q4 20258461,782,162$100.2M
Q3 20258136,214,314$47.1M
Q2 20257135,972,117$11.9M
Q1 20258246,402,107$14.5M
Q4 20248247,568,283$44.4M
Q3 20247547,790,489$56.4M
Q2 20247447,560,495$36.6M

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding OVID

FundWeight of OVIDShares (as reported)Value (as reported)Source updated
VTI Vanguard Morningstar Total Stock Market ETF0.00%5,653,216$15.1MOct 7, 2026
IWM iShares Russell 2000 ETF0.01%4,287,451$10.1MOct 8, 2026
XBI State Street SPDR S&P Biotech ETF0.07%2,812,951$6.7MOct 8, 2026
VXF Vanguard Extended Market ETF0.01%1,975,822$5.3MOct 7, 2026
VTWO Vanguard Russell 2000 ETF0.01%878,950$2.3MOct 7, 2026
IWC iShares Micro-Cap ETF0.09%522,168$1.2MOct 8, 2026
FESM Fidelity Enhanced Small Cap ETF0.02%516,121$1.2MOct 8, 2026
ITOT iShares Core S&P Total U.S. Stock Market ETF0.00%343,000$809.5KOct 8, 2026
AVSC Avantis U.S. Small Cap Equity ETF0.02%257,756$608.3KOct 8, 2026
GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF0.04%192,367$455.9KOct 8, 2026
IWO iShares Russell 2000 Growth ETF0.00%170,534$402.5KOct 8, 2026
VTWV Vanguard Russell 2000 Value ETF0.02%127,926$341.6KOct 7, 2026
PRFZ Invesco RAFI US 1500 Small-Mid ETF0.01%137,464$324.4KOct 8, 2026
LABU Direxion Daily S&P Biotech Bull 3X Shares0.02%129,767$306.3KOct 8, 2026
RSSL Global X - Russell 2000 ETF0.01%78,395$185.8KOct 7, 2026

From each fund's latest holdings file on record that shows OVID's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as OVID's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for OVID reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is OVID's share of that fund.

How to Read OVID Insider Activity

Net insider sentiment is bullish over the trailing twelve months: 3 buy transactions versus 2 sales. Cluster buying by officers or directors is one of the cleaner insider signals because purchases require personal capital deployment and carry direct SEC scrutiny for material non-public information violations. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked OVID insider trading questions

How active are OVID insiders right now?
Over the trailing twelve months, Ovid Therapeutics Inc. (OVID) insiders made 3 buy transactions and 2 sale transactions. Net insider sentiment over the trailing twelve months tilts to the buy side (3 buys vs 2 sales). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are OVID insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do OVID insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.